Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 46
- Registration Number
- NCT01215292
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 277
- Registration Number
- NCT01197170
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Anastrozole 1 mg Tablets Under Fed Conditions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT01183390
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT01155960
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT01155947
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
- Conditions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 32
- Registration Number
- NCT01155089
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
- Conditions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 31
- Registration Number
- NCT01155102
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 8
- Registration Number
- NCT01153672
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 482
- Registration Number
- NCT01151215
- Locations
- 🇬🇧
Research Site, Wythenshawe, Manchester, United Kingdom
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 71
- Registration Number
- NCT01016665
- Locations
- 🇧🇷
Sao Paulo Federal University, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.